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SUMMARY
Introduction: In two, 6-month, randomized, double-blind Phase 3 trials, PA32540 (en-
teric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) compared to aspirin
alone was associated with fewer endoscopic gastric and duodenal ulcers in patients requir-
ing aspirin therapy for secondary cardiovascular disease (CVD) prevention who were at risk
for upper gastrointestinal (UGI) events. Aims: In this 12-month, open-label, multicenter
Phase 3 study, we evaluated the long-term cardiovascular and gastrointestinal safety of
PA32540 in subjects who were taking aspirin 325 mg daily for ≥3 months for secondary
CVD prevention and were at risk for aspirin-associated UGI events. Enrolled subjects
received PA32540 once daily for up to 12 months and were assessed at baseline, month 1,
month 6, and month 12. Results: The overall safety population consisted of 379 subjects,
and 290 subjects (76%) were on PA32540 for ≥348 days (12-month completers). Adverse
events (AEs) caused study withdrawal in 13.5% of subjects, most commonly gastroe-
sophageal reflux disease (1.1%). Treatment-emergent AEs occurred in 76% of the safety
population (11% treatment-related) and 73% of 12-month completers (8% treatment-
related). The most common treatment-related AE was dyspepsia (2%). One subject had a
gastric ulcer observed on for-cause endoscopy. There were five cases of adjudicated nonfatal
myocardial infarction, one nonfatal stroke, and one cardiovascular death, but none consid-
ered treatment-related. Conclusions: Long-term treatment with PA32540 once daily for
up to 12 months in subjects at risk for aspirin-associated UGI events is not associated with
any new or unexpected safety events.
Introduction
Patients who have experienced a cardiovascular event, such as
myocardial infarction (MI) or ischemic stroke, or undergone inter-
ventional procedures such as angioplasty or bypass surgery are
advised to begin aspirin therapy for the prevention of secondary
cardiovascular events [1–3]. The use of aspirin therapy, however,
has been associated with an increased risk of upper gastrointesti-
nal (GI) bleeding [4–7] as well as clinically relevant symptoms
such as dyspepsia and gastroesophageal reflux disease (GERD)
[8–10]. Bleeding complications or upper GI symptoms may reduce
the long-term compliance with aspirin therapy [8–11] and in turn
increase the rate of adverse cardiovascular outcomes [11–14].
Patients at an increased risk of aspirin-associated adverse GI
events include those with a history of previous gastric ulcer or
upper GI bleeding [15–17]. Additionally, dual antiplatelet therapy,
concurrent nonsteroidal antiinflammatory drug (NSAID) therapy,
and increased age are also risk factors for upper GI events [5,6,15–
18]. Aspirin users have an approximate 2-folder higher increased
risk of upper GI complications, including bleeding [4,5,19–21]. In
a recent case–control study, aspirin combined with the antiplatelet
therapy increased upper GI bleeding risk from an odds ratio (OR)
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of 1.8 (aspirin alone) to 6.7, and aspirin + NSAIDs had an OR of
3.6 [5]. Regarding aging, analysis from a systematic review found
an approximate 3-fold increase in GI complications (peptic ulcer
and/or GI bleeding) as patients age from 50–54 years to 70–
74 years [18].
Proton pump inhibitor (PPI) therapy reduces the risk of aspirin-
associated upper GI events and is recommended for patients at an
increased risk [15,16]. However, several studies suggest that there
are treatment gaps with the co-prescribed prophylactic PPI pre-
scriptions and/or use [22–35]. Specifically, when PPIs are co-pre-
scribed, adherence rates are often suboptimal, leaving patients at
risk for adverse upper GI outcomes [27,28,32,33,35]. The develop-
ment of these GI side effects may in turn lead to poor compliance
and even discontinuation of aspirin therapy [8–11,36]. Discontin-
uation of aspirin therapy has been associated with a 40–60%
increased risk of secondary cardiovascular events, including MI
and stroke [12,13]. Beyond patient education through healthcare
initiatives reinforcing the importance of medication persistence,
an integrated delivery system that would ensure maximal adher-
ence to PPI administration may be clinically helpful and result in
better persistence of aspirin use and fewer therapy discontinua-
tions.
PA32540 (enteric-coated aspirin 325 mg + immediate-release
omeprazole 40 mg) is a coordinated delivery tablet consisting of
an enteric-coated aspirin core surrounded by an outer layer con-
taining immediate-release omeprazole, and the pharmacokinetics
and pharmacodynamics have been previously published [37]. The
efficacy of the coordinated delivery of a PPI has been tested in two
randomized, double-blind 6-month clinical trials, demonstrating
that PA32540 was associated with a significantly lower rate of
endoscopic gastric and/or duodenal ulcers compared with aspirin
therapy alone (3.4% vs. 11.6%, respectively; P < 0.001) [38].
As the value of effective aspirin therapy for cardiovascular pro-
tection/disease is dependent upon persistent use over time, this
long-term, open-label study with PA32540 was conducted to
simultaneously evaluate cardiovascular and GI safety for a period
of 12 months.
Methods
Study Design and Patients
This was a Phase 3, open-label study that evaluated the 12-month
use of PA32540 in adults requiring aspirin therapy for the sec-
ondary prevention of cardiovascular/cerebrovascular events. The
study protocol and amendments were approved by a central Insti-
tutional Review Board (IRB) for all study sites except 2 that used
their local IRB. The study was conducted in accordance with the
Declaration of Helsinki and good clinical practice. All subjects pro-
vided written informed consent prior to undergoing any study
procedures.
Eligible subjects were male or nonpregnant, nonbreastfeeding
females taking aspirin 325 mg daily (defined as at least 5 days/
week) for the secondary prevention of cardiovascular/cerebrovas-
cular events for ≥3 months and who were expected to use daily
aspirin 325 mg for ≥6 months. Subjects had to be ≥55 years old or
between 18 and 54 years with a documented history of gastric or
duodenal ulcer within the 5 years before the study enrollment.
Subjects also had to have a diagnosis or history of at least one of
the following: MI, ischemic stroke, transient ischemic attack
(TIA), coronary artery bypass graft (CABG), percutaneous coro-
nary intervention (PCI) with or without stent, carotid endarterec-
tomy, or established, clinically significant coronary and other
atherosclerotic vascular disease (i.e., at high risk for surgical inter-
vention or for MI, TIA, stroke, if left untreated), including angina
(stable or unstable), peripheral arterial disease, atherosclerotic
aortic disease, or carotid artery disease. Key exclusion criteria
were participation in a previous PA32540 clinical research study,
the known presence of current gastric, duodenal, or esophageal
ulcer, H. pylori-positive stool antigen test at screening, history of a
revascularization procedure (i.e., CABG, percutaneous translumi-
nal coronary angioplasty, or carotid endarterectomy) <6 months
prior to screening, history of serious upper GI event (e.g., bleed-
ing, perforation, or obstruction), any GI disorder or surgery lead-
ing to impaired drug absorption, or the presence of any chronic or
uncontrolled acute medical illness that would endanger the
subject if he/she participated in the study.
Enrolled subjects were instructed to take 1 tablet of PA32540
each morning on an empty stomach with a glass of water approxi-
mately 1 h before eating. The tablet was to be swallowed whole
and not crushed, chewed, or broken. Subjects taking concomitant
NSAID therapy were instructed to take PA32540 at least 2½ h
prior to NSAID dosing throughout the study [39] and were to self-
report any NSAID use to study staff.
Following the baseline visit, subjects returned to the clinic for
safety assessments at months 1, 6, and 12 (final visit). Safety
assessments included adverse event (AE) collection, clinical labo-
ratory tests, vital signs, and physical examination. In between
clinic visits, subjects were contacted monthly by telephone by
study personnel to reinforce compliance with the study medica-
tion and address any safety issues. Serious adverse events (SAEs)
were monitored from the time of signed informed consent until
28 days following the participation in the study. Nonserious AEs
were monitored from the start of study drug until the last day of
participation in the study. AEs were coded using MedDRA (Medi-
cal Dictionary for Regulatory Activities) version 12.1 for preferred
terms and classification of system organ class (SOC). Laboratory
tests were analyzed by a central laboratory.
All investigator-reported potentially clinically significant upper
GI events and cardiovascular events from the Phase 3 program
(two double-blind trials [38] and the present open-label trial)
were sent to either an independent GI Clinical Event Committee
(authors: JG, AL, JS, GE, BC) or an independent Cardiovascular
Review Committee (DW [author], CO, AM—see Acknowledg-
ments) for adjudication based on a priori defined set of criteria as
previously described [38]. For the purposes of blinding the com-
mittees, all potential events were reported without identifying
from which of the three studies it originated. This ensured that all
adjudicated events were assessed blinded to subject treatment and
study.
Statistical Analysis
Data were summarized for categorical and ordinal measures by
reporting the frequency and percentage of subjects in each cate-
gory. Means, standard deviations (SD), medians, minimum, and
60 Cardiovascular Therapeutics 34 (2016) 59–66 ª 2016 The Authors. Cardiovascular Therapeutics Published by John Wiley & Sons Ltd
PA32540: Long-Term Cardiovascular and GI Outcomes J. L. Goldstein et al.
maximum were summarized for continuous measures. All statisti-
cal summaries were completed using SAS version 9.1 (SAS Insti-
tute Inc., Cary, NC, USA) or higher.
Approximately 400 subjects were planned to ensure that
approximately 300 enrolled subjects would have 6-month expo-
sure to PA32540 and at least 100 subjects would have 12-month
exposure to PA32540. All safety analyses were performed on the
overall safety population (i.e., all enrolled subjects who received
at least one dose of study drug) and the 12-month “completer”
population (i.e., all subjects who were on study drug for at least
348 days). A subject who completed 12 months of therapy and all
scheduled study assessments was considered to have “completed”
the study. Compliance was assessed using pill counts and informa-
tion provided by the subjects. Treatment compliance over the
entire duration of study was defined as the percentage of drug
days out of total days in the study.
Results
A total of 380 subjects enrolled in the study at 44 sites within the
United States. The first subject enrolled on November 2, 2009, and
the last subject completed on May 26, 2011. Of these subjects, 292
(76.8%) completed the study and 88 (23.2%) discontinued early
(Table 1). The overall safety population consisted of 379 subjects
(one subject did not take study drug and was not included in the
safety population), and 290 subjects were included in the 12-
month completer population (two subjects who discontinued
from the study met the 12-month completer definition, while 4
subjects who completed the study did not meet the 12-month
completer definition.). Baseline demographics and characteristics
are shown in Table 2. The majority (70%) of subjects were males,
and most (66%) of the study population was ≥65 years.
The median duration of exposure to PA32540 was 358 days in
the overall safety population, 360 days in the 6-month completer
population, and 361 days in the 12-month completer population.
In the overall safety population, 84.2% were treated for more
than 180 days (6 months). The median number of doses taken
per subject was 354 in the overall safety population and 356 and
357 in the 6- and 12-month completer populations, respectively.
The median number of doses per month was equivalent for all
three populations (29.8), reflecting the once-daily dosing of
PA32540 and few missed doses. The majority of subjects (98%
overall safety population; 99% 6-month and 12-month com-
pleters) had ≥70% compliance.
The overall treatment-emergent adverse events (TEAE) rate
was 76% in the overall safety population and 73% in the 12-
month completer population. The most common events by SOC
were infections and infestations (26% overall population, 30%
12-month completers) and GI disorders (24% overall population,
20% 12-month completers). The most frequent TEAEs in the
infections and infestations class were bronchitis, upper respiratory
tract infection (URTI), nasopharyngitis, and sinusitis. Each of
these events occurred in 4% of the overall population and in
5–6% of the 12-month completers (Table 3). The most common
Table 1 Subject disposition and analysis populations
PA32540 (N = 380)
Number of subjects (%)
Number enrolled 380 (100)
Overall safety populationa 379 (99.7)
6-months completersb 323 (85.0)
12-month completer populationc,d 290 (76.3)
Completed studyd 292 (76.8)
Discontinued early from study 88 (23.2)
Reasons for study discontinuation
Adverse events 51 (13.4)
Protocol violations 14 (3.7)
Withdrew consent 7 (1.8)
Site closure 4 (1.1)
Lost to follow-up 2 (0.5)
Othere 10 (2.6)
Enrolled: met all inclusion/exclusion criteria and received treatment
assignment. Completed: completed 12 months of therapy and all sched-
uled assessments. aAll enrolled subjects who received at least one dose
of study medication. b6-month completers: on study drug at least
168 days. c12-month completers: on study drug at least 348 days. dTwo
subjects discontinued from the study, but met the 12-month completers
definition, while 4 subjects who completed the study did not meet the
12-month completers definition. eOther included investigator/sponsor
request, need for medical procedure or change in medication, exclusion
criteria met, moving out of state.
Table 2 Baseline demographics and characteristics
Overall safety
population,
N = 379
12-month
completers,
N = 290
Age (years)
Mean (SD) 67.3 (7.8) 67.6 (7.7)
<55, n (%) 9 (2.4) 4 (1.4)
55–64, n (%) 121 (31.9) 89 (30.7)
≥65, n (%) 249 (65.7) 197 (67.9)
Male gender, n (%) 266 (70.2) 204 (70.3)
Race, n (%)
White 347 (91.6) 265 (91.4)
Black/African American 17 (4.5) 11 (3.8)
American Indian/Alaska Native 10 (2.6) 10 (3.4)
Other 5 (1.3) 4 (1.4)
Ethnicity, n (%)
Hispanic or Latino 27 (7.1) 21 (7.2)
Not Hispanic or Latino 352 (92.9) 269 (92.8)
Weight (kg), mean (SD) 90.1 (18.8) 89.9 (18.6)
BMI (kg/m2), mean (SD) 30.5 (5.4) 30.4 (5.3)
History of gastric or duodenal
ulcer, n (%)
39 (10.3) 27 (9.3)
History of ulcer within past
5 years, n (%)
13 (3.4) 9 (3.1)
History of diabetes, n (%) 136 (35.9) 101 (34.8)
History of MI, n (%) 141 (37.2) 105 (36.2)
History of stroke, n (%) 26 (6.9) 21 (7.2)
NSAID use during study
(≥7 consecutive days), n (%)
68 (17.9) 55 (19.0)
Clopidogrel use at any time
during the study, n (%)
71 (18.7) 48 (16.6)
MI, myocardial infarction.
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GI events were diarrhea, dyspepsia, and nausea, which were each
reported in 4–5% of the overall population and in 2–5% of the
12-month completers (Table 3). Gastroesophageal reflux disease
was reported in 1.8% of the overall safety population and in 0.7%
of the 12-month completers (Table 3). The incidence of TEAEs
was higher in NSAID users versus nonusers (94% vs. 71% in the
overall safety population, P < 0.001).
Onset of TEAEs by treatment window was determined for only
those events with valid onset dates. There were a total of 876 such
events, and, consistent with the above data, most were in the SOC
of infections and infestations (135/876, 15.4%) and GI disorders
(135/876, 15.4%). The majority of GI events, including symptoms
such as nausea, dyspepsia, and gastroesophageal reflux disease,
occurred in the first 30 days of the study (46/876, 5.3%), with an
overall event rate of 8.6% in the first 90 days of the study. In
total, the incidence of GI events was 10.3% in the first 6 months
of the study and 5.1% in the last 6 months.
Adverse events considered to be treatment-related by the study
investigators were reported for 11% of subjects in the overall
safety population and in 8% of subjects in the 12-month com-
pleter population. Dyspepsia was the most frequent treatment-
related, treatment-emergent individual adverse event (2% in both
populations) and the only individual TEAE related to study treat-
ment that occurred in ≥2% of subjects. Treatment-related GERD
was reported for 3 subjects (0.8%) in the overall safety population
and in 1 subject (0.3%) of the 12-month completers.
Gastrointestinal events were the most common reason for
study discontinuation due to AEs (Table 4). Of the 51 subjects
(13.5%) who discontinued from the study due to AEs, 15 (4%)
were due to GI disorders. Gastroesophageal reflux disease was
the most frequent of these events (four subjects, 1.1%) and the
only event to have occurred in >1% of subjects; in two subjects
(0.5%), the investigator considered GERD to be treatment-
related. Abdominal upper pain caused study discontinuation in
3 subjects (0.8%) and was considered treatment-related by the
investigator in 2 (0.5%) of the subjects. Dyspepsia caused study
discontinuation in two subjects (0.5%), and in one subject
(0.3%), the investigator considered the event to be treatment-
related.
Table 3 Treatment-emergent adverse events
Preferred term
Overall safety population,
N = 379
12-month
completers,
N = 290
Number of Subjects (%)
Subjects with any TEAE 286 (75.5) 213 (73.4)
Most Common TEAEsa
Diarrhea 20 (5.3) 14 (4.8)
Back pain 16 (4.2) 15 (5.2)
Bronchitis 16 (4.2) 15 (5.2)
Dyspepsia 16 (4.2) 13 (4.5)
Nausea 16 (4.2) 7 (2.4)
Upper respiratory
tract infection
16 (4.2) 16 (5.5)
Nasopharyngitis 15 (4.0) 14 (4.8)
Sinusitis 14 (3.7) 13 (4.5)
Muscle spasms 13 (3.4) 9 (3.1)
Pain in extremity 13 (3.4) 10 (3.4)
Angina pectoris 12 (3.2) 6 (2.1)
Cough 12 (3.2) 12 (4.1)
Dyspnea 12 (3.2) 8 (2.8)
Dizziness 11 (2.9) 9 (3.1)
Peripheral edema 10 (2.6) 9 (3.1)
Subjects with any
prespecified UGI AE
55 (14.5) 31 (10.7)
Dyspepsia 16 (4.2) 13 (4.5)
Nausea 16 (4.2) 7 (2.4)
Abdominal pain upper 9 (2.4) 3 (1.0)
Vomiting 7 (1.8) 4 (1.4)
Gastroesophageal reflux
disease
7 (1.8) 2 (0.7)
Abdominal discomfort 5 (1.3) 2 (0.7)
Abdominal pain 1 (0.3) 1 (0.3)
Epigastric discomfort 1 (0.3) 1 (0.3)
Gastritis 1 (0.3) 1 (0.3)
Hyperchlorhydria 1 (0.3) 1 (0.3)
Gastric Ulcer 1 (0.3) 0
Esophagitis 1 (0.3) 0
UGI, upper gastrointestinal; TEAE, treatment-emergent adverse event.
aEvents occurring in ≥3% of subjects.
Table 4 Treatment-emergent adverse events leading to study drug
discontinuation and serious adverse events by system organ classa
System organ class
Overall safety
population,
N = 379
12-month
completers,
N = 290
Number of subjects (%)
Any adverse event leading
to study discontinuation
51 (13.5) 1 (0.3)
Gastrointestinal disorders 15 (4.0) 0
Gastroesophageal reflux disease 4 (1.1) 0
Abdominal pain upper 3 (0.8) 0
Diarrhea 2 (0.5) 0
Dyspepsia 2 (0.5) 0
Neoplasms: benign, malignant,
and unspecified
7 (1.8) 1 (0.3)
Cardiac disorders 6 (1.6) 0
Investigations 6 (1.6) 0
Any serious adverse event 55 (14.5) 34 (11.7)
Cardiac disorders 20 (5.3) 12 (4.1)
Respiratory, thoracic, and
mediastinal disorders
7 (1.8) 3 (1.0)
Neoplasms: benign, malignant,
and unspecified
6 (1.6) 2 (0.7)
Gastrointestinal disorders 5 (1.3) 4 (1.4)
Nervous system disorders 5 (1.3) 3 (1.0)
General disorders and
administration site conditions
4 (1.1) 2 (0.7)
Infections and infestations 4 (1.1) 4 (1.4)
Vascular disorders 4 (1.1) 1 (0.3)
Musculoskeletal and connective
tissue disorders
3 (0.8) 3 (1.0)
aOnly events occurring in ≥1% of subjects by system organ class are
displayed.
62 Cardiovascular Therapeutics 34 (2016) 59–66 ª 2016 The Authors. Cardiovascular Therapeutics Published by John Wiley & Sons Ltd
PA32540: Long-Term Cardiovascular and GI Outcomes J. L. Goldstein et al.
A total of 55 subjects (15%) in the overall safety population and
34 subjects (12%) in the 12-month completer population reported
at least one SAE. Only SAEs categorized as cardiac disorders
occurred in ≥2% of subjects—5% in the overall population and
4% in the 12-month completers (Table 4). One subject with a his-
tory of previous MI, triple bypass surgery, hypertension, and
hyperlipidemia died of a cerebrovascular accident with infarction
after 2 weeks on study drug; the event was considered unlikely
related to study treatment by the investigator.
While a total of eight potential events in the present study were
sent to the GI Clinical Event Committee for adjudication as poten-
tial bleeding events, only one met predefined endpoints; the sub-
ject presented with documented melena, with no site of bleeding
identified. Additionally, one subject with bright red blood per rec-
tum and abdominal pain had a gastric ulcer observed on for-cause
endoscopy; no bleeding was noted, and the patient did not meet
the predefined endpoint for a significant upper GI event. A total of
14 subjects were adjudicated by the Cardiovascular Review Com-
mittee to have events that met the predefined endpoints for a
major adverse cardiovascular event (MACE), and none were con-
sidered treatment-related (Table 5). Considering events typically
reported as serious vascular events in cardiovascular outcome tri-
als, there were 5 cases of nonfatal myocardial infarction, one case
of nonfatal stroke, and one cardiovascular death.
Discussion
Aspirin is recommended for all patients with coronary artery dis-
ease unless contraindicated [1], but the occurrence of bleeding
complications or significant GI symptoms prevents some patients
from adhering to this recommendation [8–11]. Germane to this
study, discontinuation of aspirin based on symptoms may in turn
increase the risk of subsequent cardiovascular events [8–
10,12–14]. Proton pump inhibitor therapy is recommended for
the prophylaxis of upper GI events in patients at risk for aspirin-
associated GI injury [15,16]. The risk factors that warrant PPI
therapy in aspirin users include the history of ulcer (bleeding or
nonbleeding), GI bleeding, dual antiplatelet therapy, or concomi-
tant anticoagulation or NSAID therapy [15,16]. In the absence of
any of the above GI bleeding risk factors, PPI therapy is also rec-
ommended for aspirin users who meet at least two of the follow-
ing criteria: dyspepsia or GERD symptoms, age ≥60 years, or
corticosteroid use [15].
Drawing from the literature evaluating co-prescribed PPI ther-
apy with NSAID therapy, it is well documented that adherence to
co-prescribed acid reduction therapy appears to be suboptimal
[31,33,35,40] and adherence to co-prescribed gastroprotective
medications significantly declines over time leading to increasing
risk of upper GI events [35,40]. A practical approach to address
this issue of nonadherence has been the development of fixed-
dose formulations consisting of an NSAID and an acid-suppressive
agent (e.g., diclofenac/misoprostol [41], naproxen/esomeprazole
[42], ibuprofen/famotidine [43]). Given the efficacy of PPIs in
reducing gastric mucosal injury, extending the concept of fixed
dosing to aspirin and a PPI for patients in need of aspirin prophy-
laxis for cardiovascular events has clinical face validity [44–46].
PA32540 with its novel coordinated delivery of 325 mg of aspirin
and 40 mg of immediate-release omeprazole [37] applies this con-
cept to the large at-risk population of patients who clinically
require long-term aspirin therapy [38]. Additionally, studies sug-
gest that PPI therapy has the potential to increase adherence to
aspirin therapy in patients requiring long-term treatment with
aspirin for the prevention of secondary cardiovascular events
[28,47–49].
The unique nature of this study is its focus on a clinically rele-
vant population at increased risk of upper GI events (i.e., age
≥55 years or age <55 years with a history of ulcer within 5 years
before study enrollment) who required long-term aspirin therapy
for secondary cardiovascular/cerebrovascular prevention. Given
the long-term clinical necessity of aspirin therapy in this popula-
tion, this study was designed to evaluate the overall safety of
PA32540 tablets, including GI and cardiovascular events, for a 12-
month period. Beyond upper GI events such as bleeding, a major
deterrent to long-term aspirin utilization can be the development
of dyspepsia and/or GERD-like symptoms [8–10], which are often
controlled with PPI therapy. In the Phase 3 double-blind trials, the
incidence of dyspepsia was 11% with PA32540 versus 30% with
aspirin alone (P < 0.001), while the combined events of GERD,
esophagitis, erosive esophagitis, or reflux esophagitis were
reported in 6.1% of PA32540-treated subjects versus 23.9% of
aspirin-treated subjects (P < 0.001 for the difference between
groups) [38].
Of the 380 enrolled subjects, 76% completed the study and took
PA32540 for at least 348 days. The remaining subjects left the
study due to AEs (13%) or other reasons. The most common AE
leading to study withdrawal was GERD, which occurred in 4/379
subjects (1.1%). All remaining events leading to study discontinu-
ation occurred in <1% of subjects.
Treatment-related AEs were reported for approximately 10% of
subjects, and the most common event was dyspepsia, which
occurred in 2% (8/379) of subjects. However, treatment-related
dyspepsia was the cause of study discontinuation in only 1/379
(0.3%) subjects. This rate of occurrence is significantly lower than
previously reported with aspirin [8–10]. Additionally, treatment-
related GERD was reported in 3/379 (0.8%) subjects and resulted
in study discontinuation in 2/379 (0.5%) subjects. Again, this is a
Table 5 Adjudicated major cardiovascular events
Major adverse cardiovascular
event (MACE)a
Number of subjects
(%), N = 379
Subjects with any MACEb 14 (3.7)
Cardiovascular death 1 (0.3)
Nonfatal myocardial infarction 5 (1.3)
Acute coronary syndrome 3 (0.8)
Unplanned PCI 2 (0.5)
Unplanned CABG 1 (0.3)
Confirmed ischemic stroke 1 (0.3)
Heart failure 1 (0.3)
Other cardiovascular event 1 (0.3)
PCI, percutaneous coronary intervention; CABG, coronary artery bypass
graft. aAll events were considered treatment-emergent adverse events,
except 1 case of nonfatal myocardial infarction that occurred after
study treatment discontinuation. No event was considered treatment-
related. bOne subject had two events (one nonfatal myocardial infarc-
tion and one acute coronary syndrome).
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lower rate than that reported previously in patients receiving
aspirin [8–10]. In the Phase 3 double-blind endoscopic pivotal tri-
als with PA32540, the incidence of dyspepsia was significantly
lower with PA32540 versus aspirin alone [38]. Likewise, reflux
and esophagitis events were also significantly lower with
PA32540 [38].
While these data support the benefit of long-term acid suppres-
sion in reducing aspirin-associated symptoms, PPIs also impact the
rate of upper GI complications such as bleeding and are recom-
mended by evidence-based consensus guidelines to minimize the
risk of GI bleeding in at risk patients [15,16]. Previous studies on
aspirin and NSAID users have demonstrated that lack of adher-
ence to acid suppression therapy increases the rate of upper GI
events [28,33,35], which may be circumvented by the use of an
integrated formulation.
A limitation of the present study is its open-label design and
lack of a control arm, which provide less rigorous results than
those from a randomized, double-blind trial. In particular, the
Phase 3 double-blind studies were designed to more specifically
collect upper GI symptoms compared to the present open-label
study, and therefore, they more accurately reflect the observed
difference between subjects on PA32540 versus control (EC-ASA
325 mg alone). Additionally, eligible subjects had been on aspirin
for ≥3 months before enrollment and during that time frame
reported no clinically significant GI issues precluding participation
in this study. As such, there may be some level of tolerance within
the study population, leading to lower events as reported. The
strength of this study, however, is its duration (providing up to
12 months of data on safety and tolerability) and its large clini-
cally relevant sample. However, subjects with a revascularization
procedure <6 months before enrollment as well as those who
were H. pylori positive or had a history of prior significant upper
GI event were not eligible for study enrollment. Therefore, our
findings may not be generalized to subjects at higher CV and/or
GI risk, and future study in these higher-risk populations is
required. As good clinical practice dictates, physicians should
carefully monitor newly diagnosed ischemic heart disease patients
initiating aspirin therapy.
Conclusion
No new or unexpected safety concerns were identified following
treatment with PA32540 once daily for up to 12 months in sub-
jects at risk for aspirin-associated gastric injury. The type and pat-
tern of AEs emerging in this one-year study were consistent with
prior experience with aspirin and omeprazole administered as
single agents.
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